SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Charles M. Rudin, Stephen V. Liu, Shun Lu, Ross A. Soo, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W Dumoulin, Achim Rittmeyer, Chao-Hua Chiu, Ozgur Ozyilkan, Alejandro Navarro, Silvia Novello, Yuichi Ozawa, Raymond Meng, Tien Hoang, Anthony Lee, Xiaohui Wen, Meilin Huang, Martin Reck
Institutions: Memorial Sloan Kettering Cancer Center, Georgetown University, Shanghai Jiao Tong University, Shanghai Chest Hospital, National University Cancer Institute, Singapore, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, Seoul National University, Seoul National University Bundang Hospital, Erasmus MC, Erasmus MC Cancer Institute, Taipei Veterans General Hospital, Başkent University Hospital, Vall d'Hebron Hospital Universitari, University of Turin, Wakayama Medical University, Genentech, German Center for Lung Research, LungenClinic Grosshansdorf
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4288887302